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Introduction: Recent evidence suggests that tumour lymphangiogenesis promotes lymph node metastasis, a major
prognostic factor for survival of breast cancer patients. However, signaling mechanisms involved in tumour-induced
lymphangiogenesis remain poorly understood. The expression of ezrin, a membrane cytoskeletal crosslinker and Src
substrate, correlates with poor outcome in a diversity of cancers including breast. Furthermore, ezrin is essential in
experimental invasion and metastasis models of breast cancer. Ezrin acts cooperatively with Src in the regulation
of the Src-induced malignant phenotype and metastasis. However, it remains unclear if ezrin plays a role in
Src-induced tumour angio/lymphangiogenesis.
Methods: The effects of ezrin knockdown and mutation on angio/lymphangiogenic potential of human
MDA-MB-231 and mouse AC2M2 mammary carcinoma cell lines were examined in the presence of constitutively
active or wild-type (WT) Src. In vitro assays using primary human lymphatic endothelial cells (hLEC), an ex vivo aortic
ring assay, and in vivo tumour engraftment were utilized to assess angio/lymphangiogenic activity of cancer cells.
Results: Ezrin-deficient cells expressing activated Src displayed significant reduction in endothelial cell branching
in the aortic ring assay in addition to reduced hLEC migration, tube formation, and permeability compared to
the controls. Intravital imaging and microvessel density (MVD) analysis of tumour xenografts revealed significant
reductions in tumour-induced angio/lymphangiogenesis in ezrin-deficient cells when compared to the WT or
activated Src-expressing cells. Moreover, syngeneic tumours derived from ezrin-deficient or Y477F ezrin-expressing
(non-phosphorylatable by Src) AC2M2 cells further confirmed the xenograft results. Immunoblotting analysis
provided a link between ezrin expression and a key angio/lymphangiogenesis signaling pathway by revealing
that ezrin regulates Stat3 activation, VEGF-A/-C and IL-6 expression in breast cancer cell lines. Furthermore, high
expression of ezrin in human breast tumours significantly correlated with elevated Src expression and the
presence of lymphovascular invasion.
Conclusions: The results describe a novel function for ezrin in the regulation of tumour-induced
angio/lymphangiogenesis promoted by Src in breast cancer. The combination of Src/ezrin might prove to be a
beneficial prognostic/predictive biomarker for early-stage metastatic breast cancer.Introduction
The overexpression and abnormal localization of ezrin,
the founding member of the ezrin-radixin-moesin (ERM)
family of membrane cytoskeletal crosslinkers [1], has been
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Growing evidence suggests ezrin and moesin as novel
prognostic markers of disease outcome [6,7], although the
molecular and cellular basis of their role in breast cancer
remains unclear. ERMs are expressed in a tissue-specific
manner, with ezrin predominately expressed in epithelial
cells, suggesting different ERM functions in specific cell
types [1]. Ezrin interacts with several cell signaling mole-
cules involved in tumour progression including hepatocyte
growth factor (HGF) receptor Met, β4-integrin, and Src
family kinases [8]. Ezrin is the only ERM protein to bel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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which has been shown to induce a phospho-specific
association between ezrin and its binding partners
[9,10]. In addition, ezrin Y477 phosphorylation is required
for the Src-induced invasive phenotype of cells in three-
dimensional matrix [11]. We have previously shown
that the expression of the ezrin Y477F mutant, non-
phosphorylatable by Src, significantly reduced spontan-
eous lung metastasis in a mammary fat pad engraftement
model [12].
Src is a non-receptor tyrosine kinase that is commonly
deregulated in many human cancers and plays a crucial
role in tumorigenesis and metastasis [13]. Src is com-
monly hyper-activated in human cancers and promotes
metastasis in part by inducing tumour angiogenesis
via a signal transducer and activator of transcription 3
(Stat3)/vascular endothelial growth factor (VEGF)-A sig-
naling pathway [13]. However, the role of Src in the
regulation of VEGF-C, tumour-induced lymphangiogen-
esis, and lymphovascular invasion (LVI) remains unclear.
As ezrin is a key regulator of Src activity [14-16], we ex-
amined the potential role of Src/ezrin in tumour-induced
angio/lymphangiogenesis in breast cancer. To address this
notion, we initially assessed the effect of ezrin knock-
down (KD) on angio/lymphangiogenic potential of hu-
man MDA-MB-231 (MDA231) cells expressing activated
Src. Ezrin-deficient MDA231 cells demonstrated signifi-
cant reduction in Src-induced neovascularization. Further-
more, the expression of ezrin Y477F reduced the angio/
lymphangiogenic potential of the highly invasive mouse
AC2M2 mammary carcinoma cell line. Our results sug-
gest that ezrin promotes angio/lymphangiogenic activity
by regulating Stat3 activation and expression of VEGF-
A/-C and interleukin-6 (IL-6). These findings implicate
a novel regulatory role for ezrin in Src-induced tumour
vascularization and provide a mechanistic link between




Primary human lymphatic endothelial cells (hLEC) were
purchased from Lonza (CC-2812, Walkersville, MD,
USA) and maintained in endothelial cell growth medium
provided by the supplier (EGM-2 MV, CC-3156) or basic
endothelial cell growth media (MCDB 131, Sigma-
Aldrich, St. Louis, MO, USA) at 5% CO2 and 37°C and
used at passages 2-5. The human basal-like breast cancer
cell line MDA-MB-231 (MDA231) was a gift from Dr.
Peter Siegel (McMaster University) and maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Invitro-
gen, Burlington, ON, Canada) with 10% fetal bovine
serum (FBS) at 5% CO2 and 37°C. The MDA231 cell line
expressing pWZL-hygro (empty vector) or constitutivelyactive Y527F Src (MDASrc) were a gift from Dr. Alan
Mak (Queen’s University) [17] and maintained in DMEM
with 10% FBS and selected with 100 μg/ml hygromycin.
The AC2M2 cell line is a highly metastatic lung tumour
variant selected from a CBA/J mouse-derived breast
carcinoma cell line (SP1) following three serial intra-
mammary injections of a lung metastatic nodule as
described previously (29). Two independent lentiviral
ezrin short hairpin RNA (shRNA) constructs expressed by
a pLKO.1 vector (Target sequence for shEZR-1: CCTGG
AAATGTATGGAATCAA; and shEZR-2: CCCACGTCT
GAGAATCAACAA) were purchased from Open Biosys-
tems (Thermo Fisher Scientific, Waltham, MA, USA)
and used according to the manufacturer’s instructions.
Transduced cells were selected by the addition of
4 μg/ml puromycin to the growth medium. Both con-
structs demonstrated significant KD, however the shEZR-
1 construct consistently achieved higher ezrin KD (>90%)
and was used for the majority of experiments. Ectopic
expression of the mutant Y477F ezrin and empty pCB6
vector in AC2M2 cells is previously described (23). Both
pCB6 and Y477F ezrin-expressing AC2M2 cells were
maintained in DMEM with 10% FBS plus 400 μg/ml G418
(Invitrogen) to select stable transfectants. Transient trans-
fection of pCB6 empty vector and wild-type (WT) ezrin
(EZR/WT) were performed using FugeneHD reagent
(Promega, Madison, WI, USA) according to the man-
ufacturer’s protocol. Furthermore, AC2M2 cells were
transfected with 10 nM non-silencing control or ezrin
small interfering RNA (siRNA) using Lipofectamine
2000 reagent and Opti-MEM-I reduced serum medium
(Invitrogen) as instructed by the manufacturer. A pool
of three siRNAs against mouse ezrin (ON-TARGET-
plus SMARTpool, mouse VIL2, L-046568-01-0005) and
non-targeting siRNA (ON-TARGETplus non-targeting
siRNA #2, D-001810-02-05) were purchased from Thermo
Fisher Scientific. siRNA KD of ezrin was confirmed by
western blot. To collect conditioned medium (CM),
cells were grown to 90% confluency in 100 mm culture
dishes in DMEM plus serum. After washing with sterile
serum-free media, cells were incubated in serum-free
DMEM at 37°C for 24 hours. The CM was then collected,
centrifuged at 3,000 g for 10 minutes, and concentrated
through a 5 kiloDalton (kDa) filter.Cell proliferation assay
Cell growth in vitro was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
(MTT) assay. Following seeding of equal number of
cells, MTT assay was performed according to manu-
facturer’s specifications (Sigma-Aldrich, Oakville, ON,
Canada) at 24, 48, and 72 hours. Values represent mean
O.D. (570 nm) ratios of eight wells relative to day 1.
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Western blot analysis was performed as described previ-
ously (23). Blots were blocked with 5% skim milk or bo-
vine serum albumin (BSA) and probed with anti-VEGF-A
and -C (R&D Systems, Minneapolis, MN, USA), anti-ezrin
and anti-phospho-Thr ezrin (pT567)/Radixin (pT564)/
Moesin(pT558) (pTERM, Cell Signaling, Beverly, MA,
USA), anti-Src and anti-pY416 Src (Cell Signaling), anti-
Stat3 and anti-pY705 Stat3 (Cell Signaling), anti-IL-6
(PeproTech, Rocky Hill, NJ, USA) and anti-γ-tubulin
(Sigma-Aldrich) antibodies and the appropriate second-
ary antibodies. For analysis of Src activity, we used
soluble/insoluble cell lysate fractions as described previ-
ously [16]. In brief, the soluble fraction was first extracted
by a 1-min incubation with csk buffer (50 mmol/l MES,
3 mmol/l EGTA, 5 mmol/l MgCL2, 0.5% Triton X-100,
pH 604). The remaining cellular material (insoluble frac-
tion) was rinsed quickly with cold csk buffer, and extracted
with 2 × laemmli buffer. Recombinant human IL-6 was
obtained from R&D Systems. ImageJ software was used
for densitometry analysis to calculate ratio of target bands
to loading control (γ-tubulin).
hLEC migration, tube formation, and permeability assays
Migration assay: Primary hLEC (2 × 104) were seeded
onto collagen-coated Transwell permeable inserts (8-μm
pore size, Corning, Tewksbury, MA, USA) and co-cultured
with 1 × 105 MDASrc or MDASrc shEZR cells seeded on
the companion plate. The co-culture system was incubated
in 50:50 serum-free MCDB-131:DMEM media at 37°C for
six hours, at which time the hLEC cells on top of the insert
were removed by cotton swabs and the membrane was cut,
fixed, and stained in DAPI. Multiple fields from each
membrane were imaged using a fluorescent microscope
(Olympus BX51, Olympus, Tokyo, Japan) and the number
of nuclei counted using ImageJ software.
Tube Formation Assay: hLEC were seeded at 1 × 105
cells in μ-Slide Angiogenesis plates (ibidi, München,
Germany) in 50 μl EGM-2MV media atop of 10 μl of
growth factor-reduced (GFR) Matrigel (BD Biosciences,
Burlington, ON, USA) and were stimulated with CM
from various tumour cell lines for four to six hours.
Tube formations was imaged by a phase-contrast micro-
scope (Olympus CKX41) and manually counted (n = 3).
Permeability Assay: Diffusion of TMR-dextran (aver-
age mol. wt. 2000 kDa, Invitrogen) through the intercel-
lular spaces of the lymphatic endothelial junctions was
used as a measure of macromolecular permeability across
the lymphatic barrier [18]. To form a lymphatic barrier,
hLEC (5 × 104) were seeded onto collagen-coated Transwell
inserts (8-μm pore size) 48 hours prior to overnight co-
culture with 1 × 105 MDASrc or MDASrc shEZR cells
seeded on the companion 24-well plate. The insert was then
removed and placed inside a new 24-well plate with freshmedia and the permeability of the hLEC layer was mea-
sured using a fluorescence reader (Molecular Devices, Spec-
tra Gemini XS, Sunnyvale, CA, USA) based on the amount
of TMR-dextran that diffused through the lymphatic barrier
into the lower compartment in 60 and 90 minutes.
Ex vivo aortic ring angiogenesis assay
The aorta was harvested from Sprague-Dawley rats as
described previously [19], cut into 0.5 mm ring segments
and embedded in GFR-Matrigel in a 24-well cell culture
plate. Embedded rings were covered in F12K media
containing, 1% fetal bovine serum (FBS), 1% penicillin/
streptomycin cocktail, and stimulated with CM from the
various tumour cell lines. Photographs were taken every
24 hours using a phase-contrast microscope (Olympus
CKX41) for up to 96 hours. Selected rings were stained
by immunofluorescence (IF) for endothelial cell marker
CD31 (Santa Cruz Technology, Santa Cruz, CA, USA,
#sc-1506). Endothelial cell sprouting was quantified
using ImagePro software.
In vivo Matrigel plug assay
In vivo analysis of angio/lymphangiogenesis was per-
formed by the Matrigel plug assay as previously described
[20]. All animal procedures were carried out according to
the guidelines of the Canadian Council on Animal Care
with the approval of the Queen’s University Animal Care
Committee. A total of 3 × 104 MDASrc or MDASrc shEZR
were mixed with 200 μl of cold GFR-Matrigel and injected
subcutaneously (s.c.) into six- to eight-week-old Rag2-/-
II2rγ -/- double-knockout alymphoid (Rag2γ) mice, kindly
provided by Dr. C. Tayade, (originally developed by Dr. M.
Ito at the Central Institute for Experimental Animals,
Kawasaki, Japan) or nude (NCr-Foxn1nu/nu) mice bred in
house (Queen’s University Animal Care Services). Each
mouse acted as its own control (injecting left and right
flanks) to minimize inter-subject variability. After 12 days,
the intravital imaging of blood vasculature within the
Matrigel plugs was performed using a Quorum WaveFX-
X1 spinning disk confocal system (Quorum Technologies
Inc, Guelph, ON, Canada). Mice were anesthetized with
ketamine (150 mg/kg) and xylazine (10 mg/kg) and the
jugular vein was cannulated for injection of FITC-albumin
(Sigma-Aldrich) dye to visualize vasculature. Matrigel plugs
were exposed using skin flap surgery and placed on the
microscope stage for imaging. Following intravital imaging,
Matrigel plugs were harvested and digitally photographed
with a minimum of five plugs per group. Plugs were then
fixed in 4% paraformaldehyde and paraffin-embedded for
future sectioning. Syngeneic engraftment of AC2M2 cells
(WT, Y477F, and siRNA KD) were performed in CBA/J
mice as described above with 1 × 104 cells per injection
site. Matrigel plugs containing ezrin siRNA KD cells were
harvested for analysis on day 10 post transfection. In all
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each plug was assessed by manual counting of hematoxylin
and eosin (H&E)-stained sections with at least three inde-
pendent ‘hot spots’ (areas with the highest number of
microvessel profiles at × 200 magnification) by a trained
pathologist (N.L.) blinded to the study. In addition, the
number of CD31-positive vessels within each Matrigel
plug was counted from at least three independent hot
spots (×400 magnification) to confirm histology scores. To
obtain an average vascular size, the relative cross-sectional
area of microvessels from at least three independent hot
spots per plug (×400 magnification) were tracked in ImageJ
software and reported in pixel2. To assess in vivo lymphan-
giogenesis, the relative fluorescent intensity of Lyve-1- and
podoplanin-positive cells within at least three independent
fields in each plug were calculated using ImageJ software.
Tissue microarray analysis
With the Queen’s University Research Ethics Board
approval, breast tumour specimens were collected from
63 consenting female patients who received treatment
for breast cancer at the Cancer Centre of Southeastern
Ontario at Kingston General Hospital between 2005 and
2007. Clinicopathological data (for example LVI status)
for each patient was retrospectively obtained from elec-
tronic and paper medical files by a clinical oncologist.
The cohort was limited to premenopausal women that
were 49 years of age or younger at the time of diagnosis,
had primary invasive mammary carcinomas (infiltrating
ductal and/or lobular), and staged within T1-3, N0-1, and
M0, indicators of tumour size, nodal status, and metasta-
ses, respectively. Patients with any previous history of can-
cer, bilateral breast disease or neoadjuvant chemotherapy
were excluded. Archival reduction mammoplasties from
20 consenting individuals were included as non-malignant
controls.
Immunohistochemistry and immunofluorescence
Immunohistochemical (IHC) and IF staining were per-
formed as described previously [12]. The following anti-
bodies were used overnight at 4°C: zonula occludens-1
(ZO-1) (Invitrogen, #901200), pan ezrin (Cell Signaling,
#3145), pan Src (Cell Signaling, #2109), CD31 (Santa
Cruz, #sc-1506), Lyve-1 (Merck Millipore, Darmstadt,
Germany #ab2988), and AE1/AE3 cytokeratin (Santa
Cruz, #sc-81714). Rabbit anti-mouse podoplanin anti-
body was a gift from Dr. Dontscho Kerjaschki (Medical
University of Vienna, Austria) [21]. For mouse whole
tissue section, images were obtained using a Quorum
Wave FX spinning disk confocal microscope (Quorum
Information Technologies Inc, Calgary, AB, Canada).
Staining of the tissue microarray (TMA) was performed
using an automated processor (Ventana Discovery XT;
Ventana Molecular Discovery Systems, Tucson, AZ,USA) and automated quantification analysis (AQUA)
was carried out as previously described [22]. IHC and IF
images were acquired from the stained TMA sections
by scanning with a ScanScope FL instrument, respectively
(Aperio Technologies, Vista, CA, USA). AQUA scores for
each target were obtained as described previously [23]. In
brief, IF images were used to create ‘masks’ for cytokeratin
and DAPI signals to assess the targets (Src, Ezrin) in
epithelial tumour areas annotated by a pathologist.
The signal intensity of the target was then quantified
within each compartment to generate an AQUA score,
which represents the sum of the pixel intensities for of
the Src or Ezrin, divided by the area of the mask and
normalized for exposure time. For IF staining of TMA
sections, α-rabbit EnVision +HRP-labeled polymer (Dako,
Burlington, ON, USA) and Cy5 Tyramide (PerkinElmer,
Waltham, MA, USA) were used to amplify the target
signals.
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
and analyzed with an unpaired two-tailed t test (between
two groups) or one-way analysis of variance with a Tukey-
Kramer multiple comparison post test. In analyzing TMA
results, both continuous and dichotomized (median used
as cutoff point for high and low expression) AQUA scores
were used. Unpaired t tests were used to assess associa-
tions between continuous AQUA scores and dichoto-
mized clinical factors (for example LVI). P values less than
0.05 were considered statistically significant.
Results
Ezrin KD inhibits lymphangiogenic activity of breast
carcinoma cells
In order to assess the role of ezrin in Src-mediated angio/
lymphangiogenesis, we utilized the human breast carcin-
oma MDA231 cell line expressing constitutively active
pWZL-hygro-Y527F Src (MDASrc). The expression of ac-
tive Src had no effect on ezrin activation (open conform-
ation) as indicated by steady levels of phospho-Y527 ezrin
(Figure 1A, left panel). Stable ezrin KD was achieved by
expression of a pLKO.1 lentiviral vector containing ezrin
shRNA (MDASrc shEZR) (Figure 1A, right panel). The
expression of ezrin shRNA had no significant effect on the
proliferation of MDASrc cells (Figure 1B). Next, we exam-
ined the role of Src/ezrin in tumour-induced migration
and tube formation of primary hLEC in vitro. hLEC
co-cultured with ezrin-deficient cells displayed signifi-
cant reduction in migration compared to co-culture with
MDASrc cells (Figure 1C). In the tube formation assay,
CM collected from MDASrc shEZR cells reduced the abil-
ity of hLEC to form vessel-like structures in comparison
to the MDASrc group (Figure 1D). The diffusion of TMR-
dextran beads (2000 kDa) across a lymphatic barrier
Figure 1 Ezrin KD inhibits lymphangiogenic activity of breast cancer cells. (A) The expression levels of active Src (pY416), pT567 ezrin/pT558
moesin (pTERM) and total ezrin in MDA231, MDASrc (Y527F Src in pWZL vector) and MDASrc shEZR (shRNA in pLKO.1 vector) cells were validated by
western blot. Over 85% of endogenous ezrin was depleted in our shEZR cells. (B) The relative rates of proliferation (normalized against 24 hr) of MDA231
(231), MDASrc (Src) and MDASrc shEZR (Src/shEZR) cells were assessed by an MTT assay. (C) hLEC migration assay: percent migration of hLEC, co-cultured
with MDA231 (231), MDASrc (Src), or MDASrc shEZR (Src/shEZR) cells (6 hr), is presented following normalization against the MDA231-treated group. (D)
Tube formation assay: hLEC were stimulated with CM from MDA231, MDASrc, and MDASrc shEZR for 4 hr prior to manual counting of the tube-like
structures (marked by asterisks). The histogram displays the percentage of tube formation in each group relative to MDA231 control cells. Scale bar = 50 μm.
(E) The integrity of the hLEC monolayer was assessed by the paracellular diffusion of TMR-dextran (2000 kDa). Readings are expressed in relative fluorescence
as percentage of control (collagen-coated membrane alone) (n = 3). (F) Monolayer of hLECs (5 × 105 cells) was co-cultured overnight with no cells (control),
MDASrc, or MDASrc shEZR (shEZR). The diffusion of TMR-dextran across the hLEC barrier was measured in 90 min and presented as relative fluorescence nor-
malized to the control (n = 4). CM: conditioned media; hLEC: human lymphatic endothelial cells; KD: knockdown; kDa: kiloDaltons; shRNA: short hairpin RNA.
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effect of cancer cells on vascular permeability (Figure 1E).
The diffusion of TMR-dextran across the lymphatic barrier
co-cultured with MDASrc shEZR cells was significantly
decreased when compared to MDASrc cells (Figure 1F).
Examination of cell-cell junctions in hLEC, by staining for
ZO-1, further corroborated these findings (Figure S1 in
Additional file 1).
Ezrin KD inhibits Src-induced angiogenic activity
Angiogenic properties of CM collected from MDASrc
and MDASrc shEZR cells were analyzed by stimulatingendothelial branching in Matrigel-embedded aortic ring
explants. The expression of active Src induced a robust
angiogenic response in aortic rings treated with CM
from MDASrc compared to MDA231 cells (Figure 2A).
However, ezrin KD was able to significantly reduce the
angiogenic effect of MDASrc cells. Ezrin KD in MDA231
cells, expressing endogenous WT Src and therefore less
angiogenic than MDASrc cells, also revealed noticeable
reduction in angiogenic activity compared to the MDA231
control, although the effect did not reach statistical signifi-
cance due to the short timeline of this assay. Migrating
cells from the aorta rings were predominately endothelial
Figure 2 Ezrin KD inhibits tumour-induced endothelial cell sprouting. (A) Aortic rings were stimulated with CM from MDA231 (231), MDA
shEZR (shEZR), MDASrc (Src), and MDASrc shEZR (Src/shEZR) for 96 hr prior to imaging. Endothelial cell sprouting was quantified using ImagePro
software and presented as percentage of control (bar graph; n = 4 in triplicates). ANOVA post-test analysis revealed MDASrc as the only group
with significantly higher angiogenic activity. (B) Three-dimensional reconstruction of confocal images of CD31-positive endothelial cells migrating
out of aortic ring (Scale bar = 200 μm). CM: conditioned media; KD: knockdown.
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S1 in Additional file 2).
Ezrin is required in tumour-induced angio/
lymphangiogenesis in vivo
To compare the angio/lymphangiogenic potential of
MDASrc and MDASrc shEZR cells in vivo, we performed a
Matrigel plug xenograft assay in mice (Figure 3A). The ex-
pression of both Src and ezrin KD were confirmed by im-
munostaining of tumour sections (Figure S2 in Additional
file 3). Tumours containing ezrin-deficient cells displayed a
five-fold reduction in vascular density and a 10-fold reduc-
tion in vascular luminal area compared to MDASrc plugs
(Figure 3B and C, respectively). Strong CD31 staining
confirmed the presence of blood vessels in the tumour
(Figure 3D). Tumours derived from ezrin-deficient cells
demonstrated a significant reduction in lymphangiogen-
esis compared to MDASrc cells, as indicated by lymphatic
vessel markers lyve-1 and podoplanin (Figure 3E and F,
respectively). Furthermore, intravital microscopy revealed
a robust and functional vascular network invading the
MDASrc tumours, whereas vessels in the ezrin-deficient
tumours were only found at the tumour periphery (Movie
S2 in Additional file 4). Ezrin KD in the presence of en-
dogenous Src expression in MDA231 cells also significantly
inhibited tumour-induced vascularization (Figure 3G).
The table in Figure 3H summarizes the effect of ezrin
KD on tumour-induced vascularization in the presence
or absence of constitutively activated Src. An independent
ezrin shRNA vector expressed in MDASrc cells yielded
comparable results (Figure S3, panel A in Additional file
5). In addition, repeat of the above Matrigel plug assay in
nude (Figure S4 in Additional file 6) and immunocompe-
tent (syngeneic AC2M2 graft) CBA/J mouse recipients
yielded results similar to Rag2γ mice (Figure S3, panels B-
D in Additional file 5).Y477F ezrin inhibits tumour-induced angio/
lymphangiogenesis
Ezrin Y477, a Src substrate, is required for the Src-induced
invasive phenotype in breast cancer cells [11,12]. There-
fore, we examined the angio/lymphangiogenic potential of
AC2M2 cells expressing the phosphorylation-deficient
Y477F ezrin mutant, which competes with endogenous
WT ezrin (EZR/WT) [12]. Aortic rings stimulated with
CM from Y477F mutant-expressing cells displayed signi-
ficant reduction in endothelial cell branching in compari-
son to AC2M2 cells expressing the pCB6 empty vector
(Figure 4A). Furthermore, hLEC co-cultured with Y477F
cells demonstrated reduced mobility when compared
with control cells in aTranswell migration assay (Figure 4B).
Engraftment of Y477F expressing AC2M2 cells into immu-
nocompetent syngeneic CBA/J mice revealed significant
reductions in tumour-induced angio/lymphangiogenesis
(Figure 4C and D, respectively).
Ezrin is required for Src-induced Stat3 phosphorylation
and VEGF-A/-C and IL-6 expression
Src has been shown to induce VEGF expression through
Stat3 activation [24,25]. However, it is not known whether
ezrin is required for Src regulation of the Stat3/VEGF
pathway. Our results show that Src-induced increases in
Stat3 phosphorylation (pY705), survivin expression (Stat3
target), and VEGF-A/-C expression were reversed in ezrin-
deficient MDASrc cells (Figure 5A,B). A similar pattern
was observed in CM from MDASrc and MDASrc shEZR
cells (Figure S5, panel A in Additional file 7). Furthermore,
overexpression of wild-type ezrin (EZR/WT) in the ab-
sence of constitutively active Src in MDA231 cells revealed
an increase in pY705 Stat3 phosphorylation and VEGF
expression, compared to empty vector (Figure 5C). To in-
vestigate the effect of ezrin KD on endogenous Src activity
(enriched in the cytoskeletal compartment [16]), the
Figure 3 Ezrin KD inhibits tumour-induced angio/lymphangiogenesis in vivo. (A) Matrigel plugs containing MDASrc (Src) or MDASrc shEZR
(Src/shEZR) were digitally photographed on day 12 post injection in Rag2γ mice. Tumour-induced angiogenesis was analyzed in Matrigel plugs
H&E sections for (B) MVD per selected field (manual count by trained pathologist blinded to the experiment), and (C) vessel luminal area (dots
represent the mean vascular area in each selected field in pixel2). (D) Nature of blood vasculature was confirmed by CD31 immunostaining.
(E and F) To assess tumour-induced lymphangiogenesis, Matrigel plugs were stained for lymphatic markers Lyve-1 and podoplanin followed by
quantification of relative fluorescence density of each marker (bar graphs). (G) The Matrigel plugs derived from MDA231 (231) and MDA shEZR
(shEZR) were harvested on day 20 post injection and assessed for MVD and vessel lumen area in corresponding H&E sections. (H) The effect of
ezrin KD on MVD and vessel lumen size in tumours derived from MDA231 and MDASrc harvested on days 12 and 20 is summarized. Arrowheads
in panels A and D point to microvessels in the tumour H&E sections. Inserts in panel A represent higher magnifications (×400) of areas in dotted
boxes. P values were obtained from unpaired t test statistical analysis. All scale bars = 200 μm, except panel D bar = 50 μm. H&E: hematoxylin and
eosin; KD: knockdown; MVD: microvessel density; Rag2γ: Rag2-/-II2rg-/- mice.
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Figure 4 Expression of Y477F mutant ezrin abrogates tumour-induced angio/lymphangiogenesis. (A) Aortic rings were stimulated with
CM from AC2M2 cells expressing pCB6 empty vector or Y477F ezrin and endothelial sprouting imaged (96 hr) and analyzed by ImagePro
software (n = 3, bar graph). (B) Transwell migration of hLEC co-cultured with AC2M2 or Y477F cells (6 hr) was assessed by automatic count
(ImageJ) of cells stained with DAPI. (C) Syngeneic Matrigel plug assay of AC2M2 or Y477F cells in CBA/J mice photographed on day 12 post
injection along with representative H&E sections (arrows point to microvessels). Angiogenic activity was analyzed by MVD and vessel cross-
sectional area (graphs to the right). (D) Lyve-1-positive cells (arrows) in plugs were quantified in selected hot spots by pathologist blinded to the
study. P values were obtained from unpaired t test statistical analysis. Scale bars = 50 μm. CM: conditioned media; H&E: hematoxylin and eosin;
MVD: microvessel density.
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http://breast-cancer-research.com/content/16/5/438insoluble fractions of MDA231 cell lysates were ana-
lyzed for pY416 Src levels. As shown in Figure S5, panel C
in Additional file 7, depletion of ezrin by shRNA signifi-
cantly decreased Src pY416 phosphorylation without an
effect on Src expression.
Proteomic analysis of MDA231 CM identified IL-6 as
a cytokine regulated by ezrin (data not shown) and the
IL-6/Stat3 signaling loop has been reported to promote
angiogenesis and metastasis in breast cancer [26]. Our re-
sults show that elevated IL-6 expression in MDASrc cellswas markedly reduced following ezrin KD (Figure 5D).
Ezrin depletion in MDA231 cells, expressing endogenous
WT Src, also diminished IL-6 levels in cell lysate and CM
(Figure S5, panel B in Additional file 7). Interestingly, the
inhibitory effect of ezrin KD on VEGF and Stat3 phos-
phorylation can be rescued by the addition of recombinant
human IL-6 (Figure 5F). Moreover, overexpression of EZR/
WT increased IL-6 expression compared to MDA231 cells
expressing an empty vector (Figure 5E). Next, we examined
the effect of blocking IL-6 by collecting CM from MDASrc
Figure 5 Ezrin KD blocks Stat3 phosphorylation, VEGF-A/-C, and IL-6 expression. Representative western blots display pY705-Stat3, Stat3,
and survivin (panel A) and VEGF-A/-C (panel B) levels in MDA231, MDASrc, and MDASrc shEZR lysates. γ-tubulin expression was used as loading
control. Densitometry results are presented as an average (n = 3) ratio of target protein to γ-tubulin and normalized against MDA231 controls (bar
graphs). P values were calculated using unpaired t test. (C) Cell lysates from MDA231 cells expressing the empty vector pCB6 or wild-type ezrin
(EZR/WT) were analyzed for VEGF-A, pY705 Stat3, and Stat3 levels. (D) Immunoblot analysis of IL-6 in cell lysates from MDA231 and MDASrc cells
expressing the empty vector pLKO.1 or shEZR vector. (E) Immunoblot analysis of IL-6 levels in cell lysate from MDA231 cells expressing the empty
vector pCB6 or wild-type ezrin (EZR/WT). (F) Immunoblot analysis of VEGF-A, pY705 Stat3, and Stat3 in MDA231 shEZR cells treated with vehicle
alone or 20 ng/ml recombinant human IL-6 for 20 hr. (G) The angiogenic activity of CM collected from confluent MDASrc in the presence of
α-IL-6 neutralizing antibody or non-immune IgG was assessed using the aortic ring assay. Endothelial cell sprouting was quantified using
ImagePro software and presented as percentage of control (bar graph). Identical amount of α-IL-6 antibody was added to rings in the MDASrc
group to control for the direct effect of antibody on endothelial cell sprouting. Panels C-F: relative densitometry values are displayed under
corresponding bands (normalized against γ-tubulin). CM: conditioned media; IgG: immunoglobulin G; IL-6: interleukin-6; KD: knockdown; Stat3:
signal transducer and activator of transcription 3; VEGF: vascular endothelial growth factor.
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http://breast-cancer-research.com/content/16/5/438cells in the presence of an IL-6 neutralizing antibody [27].
The presence of IL-6 antibody, compared to non-immune
IgG-treated CM, significantly reduced the angiogenic po-
tential of MDASrc CM in an aortic ring assay (Figure 5G).Ezrin and Src expressions correlate with lymphovascular
invasion in breast cancer
Primary breast tumour cores from a nested cohort of a
63-patient TMA were assessed for total Src and ezrin
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http://breast-cancer-research.com/content/16/5/438expression using an IF-based AQUA. IHC staining was
initially used to validate Src and ezrin antibodies and to
assess their localization in normal and tumour breast
tissue. Src and ezrin exhibited a strong apical staining in
breast ductal epithelium and diffuse cytoplasmic staining
in the breast tumour (Figure 6A). Multiplex IF staining
with cytokeratin (epithelial marker) allowed for quantifi-
cation of Src and ezrin expressions in the epithelial com-
partment and exclusion of the stroma region. As shown
in Figure 6B, a diverse range of Src and ezrin expression
was detected in the tumour tissues. Dichotomized high
ezrin AQUA scores (based on median) revealed a signifi-
cant association between high Src and ezrin expression
(Figure 6C). Furthermore, the correlation analysis between
continuous AQUA scores and dichotomized clinico-
pathological data revealed that high expression of Src
and ezrin were significantly associated with LVI in
breast cancer (Figure 6D and E, respectively). A trend
between high ezrin expression and positive LN status was
also suggested, but did not reach statistical significance
(not shown).Figure 6 Src and ezrin expression in human breast cancer. (A) IHC sta
ezrin antibodies. Scale bars = 75 μm. (B) Cy5 IF staining was used to assess
TMA. Representative tumour cores with high and low expression of Src and
Scale bars = 100 μm. (C) Association between dichotomized ezrin AQUA sc
IF-stained 63-TMA. (D, E) Continuous AQUA scores of total Src and ezrin w
were assessed using the unpaired Student’s t test. Associations were consid
analysis IF: immunofluorescence; IHC: immunohistochemistry; LVI: lymphovDiscussion
We and others have previously shown an intrinsic regu-
latory role for ezrin in cancer invasion and metastasis
[11,12,28-30]. Despite the growing evidence pointing to
ezrin as a key promoter of tumour metastasis, the molecu-
lar basis of ezrin function remains poorly understood. In
the present study, we demonstrate that ezrin-deficient
cells display a significant reduction in VEGF-A/-C expres-
sion and angio/lymphangiogenic activity, thus indicating a
novel extrinsic mechanism by which ezrin regulates early
stages of metastasis. We further show that ezrin tyrosine
477, a Src phosphorylation site, plays a regulatory role in
tumour-induced angio/lymphangiogenesis. Our findings
modify previously described mechanisms in Src-induced
tumour angiogenesis [13] by defining a requirement for
ezrin and its phosphorylation by Src in this process.
We suggest that the overexpression of Src and ezrin,
commonly observed in a variety of cancers, promotes
metastasis by inducing tumour blood and lymphatic
vascularization in addition to previously described in-
duction of invasive phenotype in tumour cells [11,12].ining of breast normal and tumour tissue was used to validate Src and
the expression levels of Src and ezrin in the 63-patient breast cancer
ezrin are presented. Images were acquired using Aperio ScanScopeFL.
ores (cutoff: median) and continuous Src AQUA scores based on
ere correlated against dichotomized LVI status. Statistical associations
ered significant when P <0.05. AQUA: automated quantification
ascular involvement; TMA: tissue microassay.
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http://breast-cancer-research.com/content/16/5/438The novel role for ezrin in the regulation of tumour
lymphangiogenesis is consistent with previous clinical
reports suggesting a strong association between ezrin
and positive LN status in breast cancer [3,4]. Our results
suggest that a positive correlation exists between high
ezrin expression and LVI in breast cancer, providing a
rational for the presence of LN metastasis in tumours
with high ezrin expression [4,31]. A trend of association
between high ezrin expression and positive LN status
was also suggested in our TMA analysis and is currently
being validated in a larger breast cancer cohort. Further-
more, the majority of breast tumours expressing high
levels of ezrin are also strongly positive for Src, thus
providing clinical support for the previously described
co-operative function of Src and ezrin in the experimen-
tal cancer models [11,12,15].
Our observed comparable growth curves for cells ex-
pressing active Src (MDASrc) and ezrin shRNA (MDASrc
shEZR) exclude the possibility that the reduction in angio/
lymphangiogenesis is a result of reduced proliferation rate
of ezrin-deficient cells. This observation is consistent with
our previous demonstration that expression of mutant
ezrin Y477F does not inhibit growth in three-dimensional
cell colonies or primary tumour xenografts [12]. More-
over, we observed no significant difference in the growth
rate of MDASrc and MDASrc shEZR tumours in a Rag2γ
xenograft mammary fat pad model (unpublished data).
Osawa et al. also demonstrated, using a medulloblastoma
model, that the overexpression of ezrin promotes invasion
without causing a change in the proliferation rate of
cancer cells [32].
Tumour-associated immune cells play a critical role in
the promotion of neovascularization [33]. Therefore, in
addition to the Rag2γ model (T, B, NK cell deficient), we
examined the effects of ezrin KD and Y477F mutation in
nude (mature T cell deficient) and immunocompetent
histocompatible CBA/J mouse models. All three animal
models yielded similar reductions in vascularization of
ezrin-deficient or Y477F ezrin-expressing tumour cells.
Together, these findings support the requirement of ezrin
in tumour-induced angio/lymphangiogenesis regardless of
T, B, and NK cell status of host recipients.
An indirect link between Src activity and lymphangio-
genesis was previously implied by an observed reduction
in VEGF-C secretion, a potent lymphangiogenic factor
[34], in MDA231 cells treated with the Src kinase inhibi-
tor, PP1 [35]. Our results identify a direct requirement
for ezrin in Src-induced VEGF-C expression in breast
carcinoma cells. Furthermore, our demonstrated regula-
tory role of ezrin in the expression of IL-6 is highly rele-
vant as high levels of IL-6 correlate with increased
metastatic potential and poor outcome in breast cancer
[36]. A signaling pathway linking IL-6 with Stat3 activa-
tion and VEGF expression has been previously described[37]. In addition, Chang et al. have recently described a
regulatory role for a Stat3/IL-6 positive feed-forward loop
in promoting angiogenesis and metastasis [26]. Our find-
ings further build on these models by suggesting a role
for ezrin in the regulation of IL-6 expression and Stat3
activation leading to the upregulation of VEGF-A/-C and
tumour angio/lymphangiogenesis. As rhIL-6 was able to
induce Stat3 activation and VEGF-A expression in ezrin-
deficient cells, we believe that ezrin operates upstream of
IL-6/Stat3 by positively regulating IL-6 transcription.
Interestingly, nuclear factor κB activity, an important
transcription factor in activation of IL-6 gene, requires
ezrin binding in the regulation of IκB phosphorylation [30].
The exact mechanism by which ezrin and Src interact
to regulate the Stat3/VEGF pathway is not fully under-
stood. Src binds via its SH2 domain to pY190 ezrin and
phosphorylates ezrin at Y145, resulting in a reciprocal
stabilization of Src activity [14]. A similar regulation of
Src activity has been reported for other Src substrates,
such as focal adhesion kinase (FAK) [38], the tyrosine
phosphatase Shp-2 [39], and the adapter protein p130CAS
(CAS) [40]. Src also phosphorylates ezrin Y477 [9], a
tyrosine residue unique to this ERM family member.
Heiska et al. and our group have recently demonstrated a
role for ezrin Y477 in Src-induced anchorage-independent
invasive growth in three-dimensional environment [11]
and in local invasion and metastasis in a breast cancer
xenograft model [12]. This result is in line with our ob-
served reduction in angio/lymphangiogenesis in tumours
derived from ezrin Y477F-expressing cells. The reduction
of Src activity (pY416) in ezrin-deficient cells following
short-term (2 hr) seeding on a collagen-coated surface,
suggests a requirement for ezrin in Src activation. Consid-
ering ezrin’s role as a crosslinker and scaffold protein, it is
plausible for ezrin to act as a docking site for Src and its
regulators.
Hepatocyte growth factor (HGF) and its receptor Met
play a significant role in tumour progression partly
through upregulation of Src, Stat3 activity, and VEGF
expression [41,42]. HGF/Met-mediated Stat3 activation
can in turn upregulate the expression of IL-6 [43], which
feeds into the Stat3/IL-6 forward loop [26]. Interestingly,
Y477 ezrin phosphorylation is required by Src in HGF-
induced scattering of epithelial cells [10]. The potential
involvement of HGF/Met in Src/ezrin-mediated tumour
angio/lymphangiogenesis is consistent with our recent
finding demonstrating Src/ezrin co-operation increased
Met activation and extracellular matrix degradation,
characteristic of an invasive phenotype in breast cancer
[44]. Furthermore, Zaarour et al. have reported a novel
mechanism by which Y477 ezrin regulates the stability
and activity of Met receptor, by interacting with the ubi-
quitin ligase WWP1, which is overexpressed in human
breast and prostate cancers [45]. Therefore, ezrin silencing
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http://breast-cancer-research.com/content/16/5/438or Y477F mutation can result in the downregulation of
Src/Met-dependent Stat3 activation followed by a reduc-
tion in IL-6/VEGF-A/-C expression and angio/lymphan-
giogenic activity.
Conclusions
Further understanding of mechanisms involved in the
early stages of metastatic progression is a prerequisite
for discovery of novel prognostic/predictive biomarkers.
The present study provides novel insights into the regu-
latory role of ezrin and Src in tumour-induced angio/
lymphangiogenesis, a precondition for early tumour cell
dissemination. Further studies are required to elucidate
the role of the Src/ezrin pathway in the invasion process
and its potential as a novel prognostic/predictive biomarker
for early-stage metastatic phenotype in breast cancer.
Additional files
Additional file 1: Figure S1. Cell-cell junction marker, ZO-1, staining of
hLEC barrier. hLEC co-cultured overnight with MDASrc or MDASrc shEZR
cells were stained for the cell junction marker ZO-1 and DAPI and imaged
by spinning disk confocal microscopy. In absence of ezrin expression,
disruptions of hLEC tight junction, which effect vascular permeability,
induced by tumour cells are markedly reduced. Scale bars = 50 μm.
Additional file 2: Movie S1. Endothelial cells sprouting and migration
from the aortic ring wall. Three-dimensional compilation of z-stacks
obtained by spinning disk confocal microscope following immunostaining
with endothelial cell marker CD31 (red) and DAPI (blue). Scale bar = 200 μm.
Additional file 3: Figure S2. Src/ezrin expression in Matrigel plugs.
Matrigel plugs sections were immunostained for Src and ezrin to confirm
their expression on day 12 post injection. Scale bars = 200 μm.
Additional file 4: Movie S2. Intravital imaging of vascular network
within Matrigel plugs. Functional blood vessels within the Matrigel plugs
were visualized by intravenous injection of FITC-albumin in anesthetized
mice. Panel on the right shows time-lapse and z-stacks compilation
intravital microscopy of vessels invading the MDASrc plugs. A confocal
image of a vessel in the periphery of MDASrc shEZR plug is shown on
the right. The dotted line represents the boundary of the plug.
See Methods for further information. Scale bars = 200 μm.
Additional file 5: Figure S3. Validation of Ezrin shRNA knockdown. (A)
A second ezrin shRNA (shEZR-2 in pLKO.1 vector) was used to generate a
stable ezrin KD line (MDASrc shEZR-2). Repeat of Matrigel plug assay with
MDASrc and MDASrc shEZR-2 cells displayed comparable reductions in
tumour-induced angiogenesis as the MDASrc shEZR-1 cell line, ruling out
non-specific effects of shRNA-1 ezrin KD. P value was obtained from
unpaired t test analysis. (B) Syngeneic engraftment of Matrigel + AC2M2
cells transfected with non-silencing (siCont) or ezrin (siEZR) siRNA in CBA/
J mice demonstrated significant reduction in angio/lymphangiogenesis in
the presence of a fully functional immune system, as shown by MVD and
vessel size assessment in H&E sections (graphs). Scale bars = 500 μm.
(C) Lymphangiogenic activity in the same plugs (panel B) was assessed
by quantification of Lyve-1-positive endothelial cells (arrows) in selected
hot spots. (n = 4, at least three ‘hot spots’ examined per plug).
Scale bars = 50 μm. (D) Confirmation of ezrin KD in AC2M2 by pooled
siRNAs at 24, 48, and 72 hr post-transfection. A universal non-silencing
siRNA (siCont) was used as control.
Additional file 6: Figure S4. Matrigel plug assay in nude mice.
GFR-Matrigel containing MDASrc or MDASrc shEZR cell lines were
injected s.c. and harvested on day 12 post injections. Tumour-induced
angiogenic activity was assessed by MVD and vessel cross-sectional area
in selected hot spots of H&E sections (n = 4). Scale bars = 200 μm. Inserts
were imaged using a 40X objective.Additional file 7: Figure S5. Reduced Src activity in ezrin-deficient cells
and decrease in VEGF-C/IL-6 secretion. (A) Representative western blot
displays VEGF-C levels in conditioned media collected (24 hr) from
confluent MDA231, MDASrc (pLKO.1), and MDASrc shEZR (shEZR).
Densitometry analysis represents average of three blots normalized
against MDA231. Our VEGF-A antibody, unlike cell lysates, did not pick up
any bands in the CM, perhaps due to post-translational modification of
the target epitope. (B) Immunoblots of IL-6 in CM and cell lysates from
MDA231 (pLKO.1) and MDA231 shEZR cells. Results from densitometry
analysis are shown below each band and normalized against γ-tubulin.
(C) Following serum starvation (2 hr), suspension of cells (30 min), and
seeding on collagen-I-coated plates (2 hr), soluble and insoluble fractions
of MDA231 and MDA231 shEZR cell lysates were analyzed for pY416 Src,
Src, pT567 ezrin (pTERM antibody), and ezrin. Src pY416 levels in insoluble
fraction of MDA231 (231) and MDA231 shEZR (shEZR) cell lysates were
compared by densitometry (bar graph). P values are calculated by
unpaired t test.
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